Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

DRUG2 trials

Sponsors

Zhengzhou Gensciences Inc

Conditions

Hemophilia A

Phase 3

An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.

CompletedNCT04456387

Zhengzhou Gensciences IncHemophilia A

Start: 2020-10-15End: 2021-09-30Updated: 2023-12-13

Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A

CompletedNCT04845399

Zhengzhou Gensciences IncHemophilia A

Start: 2021-04-16End: 2021-06-26Updated: 2023-08-29

Related Papers

Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study

Blood2022-11-15